Amgen, Swedish Orphan Biovitrum deal

Swedish Orphan and Amgen amended a 2008 deal to grant Swedish Orphan full rights to Kineret anakinra. Swedish Orphan previously held worldwide rights to the IL-1 receptor antagonist to treat rheumatoid arthritis and four Orphan indications. Kineret is approved in the U.S. and EU to treat RA and in the U.S. to treat neonatal onset multisystem inflammatory disease (NOMID), the most severe form of cryopyrin-associated periodic syndromes (CAPS). Swedish Orphan reported 1H13 Kineret sales of SEK256.4 million ($38.2 million) (see BioCentury, Sept. 22, 2008). ...